Apogee Therapeutics, Inc.
NASDAQ:APGEBiotechnology
+$1.05 today
- Market cap
- $8.36B
- Beta
- 0.62
- P/E (TTM)
- -22.7
- EPS (TTM)
- -$3.94
Volume 0.00M
Average 0.97M
APGE Cash & Equivalents
Cash on hand and highly liquid investments that can be converted to cash almost immediately.
Apogee Therapeutics, Inc.NASDAQ: APGE
Cash & Equivalents · Q2 FY2026 · quarter ended Jun 2026
Cash & equivalents falls 15.0% from a year ago
Cash & equivalents stood at $105.57M at the end of Q2 FY2026, down 15.0% from a year earlier and down 76.6% from the prior quarter. Over 3 fiscal years it compounded at -4.7% a year.
Context
- Cash & equivalents amounted to 7.9% of total assets at the end of Q2 FY2026, down 11.0 pp from a year earlier.
- Cash & equivalents increased in 1 of the last 3 fiscal years.
What to watch
Whether cash & equivalents keeps falling in the next quarterly balance sheet after a -15.0% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Cash & Equivalents history
USD · from the balance sheet
- Latest · FY2025
- 131.55M USD
- Year-over-year change
- -7.2%
- 3-year CAGR
- -4.7%
| Period | Period end | Cash & Equivalents | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 131.55M | -7.2% |
| FY2024 | 2024-12-31 | 141.79M | +19.8% |
| FY2023 | 2023-12-31 | 118.32M | -22.1% |
| FY2022 | 2022-12-31 | 151.89M | — |
Cash & Equivalents vs competitors
How APGE compares with its peers on the latest reported figures
- Peers report in different currencies, so cash & equivalents is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -15.0% is the 5th highest of 10, against a peer median of -17.0%.
- Cash & equivalents amounts to 7.9% of total assets for APGE, versus a peer median of 13.5%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
AAPGAscentage Pharma Group International | Dec 2025 | CN¥2.47B CNY | +99.9% | +18.8% | 62.3% |
| Jun 2026 | $607.52M USD | -17.0% | -12.3% | 56.5% | |
| Sep 2026 | $460.7M USD | +65.2% | +4.7% | 27.4% | |
| Jun 2026 | $182.05M USD | +292.7% | +88.9% | 22.0% | |
| Mar 2026 | $175M USD | +37.7% | +48.3% | 13.5% | |
| Jun 2026 | $105.57M USD | -15.0% | -4.7% | 7.9% | |
IRONDisc Medicine, Inc. | Sep 2026 | $89.98M USD | -36.0% | -22.3% | 12.9% |
| Sep 2026 | $82.56M USD | -21.0% | +51.5% | 6.9% | |
| Mar 2026 | $62.43M USD | -40.6% | -46.2% | 9.7% | |
| Sep 2026 | $28.25M USD | -37.4% | -28.3% | 2.7% | |
| Peer median (excluding APGE) | — | -17.0% | +4.7% | 13.5% | |
Competitors are the stored peer set for APGE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Apogee Therapeutics, Inc.
NASDAQ:APGE
Intrinsic Alpha fair value
Locked
Current Price
$135.07
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.